Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • BillionCheers Introduces Immunity Boosting Probiotic Drink for Kids

    Gurgaon headquartered leading nutraceutical manufacturer Fermentis Life Sciences has introduced an Immunity boosting Probiotic drink for kids - Junior Immunity Booster Probiotic -under its family nutrition brand – BillionCheers.

  • Medtronic launches smallest pacemaker with Atrioventricular synchrony

    India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of Micra AV - a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to atrioventricular (AV) block patients via a minimally invasive approach. The device is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart

  • Glenmark launches bioequivalent of Tiotropium Bromide for treatment of COPD

    Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

  • Strides partnered with Ennaid for AI based COVID-19 medicine

    Strides Pharma Science Limited announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

  • Novavax COVID-19 Vaccine 90% efficacy in Phase 3 Trial

    Novavax, Inc announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

  • NATCO receives approval for Carfilzomib Vials ANDA in the US market

    Natco Pharma Limited is pleased to announce that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received approval for its Abbreviated New Drug Application (ANDA) for Carfilzomib Vials ANDA (generic for KYPROLIS), from the U.S. Food and Drug Administration (USFDA).

  • New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation

    Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery. They concluded that ORi-guided oxygen titration may reduce hospital stay and increase patient safety.

  • Indian Pharmaceutical industry affected by counterfeiting challenges

    Indian Pharmaceutical industry amongst five sectors affected by counterfeiting Incidents reported by Authentication Solution Providers Association, ASPA. There was a sharp spike in crimes related to illicit liquor, smuggling of tobacco products and pharmaceutical products especially PPE kits and sanitizers, etc during the COVID-19 lockdown.

  • FDA Grants Accelerated Approval for Alzheimer’s Drug

    The U.S. Food and Drug Administration approved Aduhelm for the treatment of Alzheimers, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

  • Senolytics reduce COVID-19 symptoms in preclinical studies

    Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body. In preclinical studies, the senolytic drugs discovered at Mayo significantly reduced inflammation, illness, and mortality from COVID infection in older mice. The findings appear in the journal Science.

Subscribe to Pharma News